Skip to main content
Premium Trial:

Request an Annual Quote

Pacific Biosciences' Stock Climbs on Hunkapiller Stock Buy

NEW YORK (GenomeWeb News) – Shares of Pacific Biosciences climbed 12 percent in Friday afternoon trade after regulatory documents filed Thursday showed that Mike Hunkapiller, the firm's chairman, president, and CEO, had purchased 200,000 shares of the firm's stock on the open market.

According to a Form 4 filed with the US Securities and Exchange Commission, Hunkapiller bought the shares in multiple transactions at prices ranging from $3.51 to $3.72 and at an average price of $3.61 per share. Hunkapiller now owns 1.7 million shares of the firm's stock, according to the filing.

Investors greeted the filing enthusiastically, sending PacBio's stock up $.43 to $4.01 in Friday afternoon trade on the Nasdaq. Its shares had traded as high as $4.22 earlier in the day.

PacBio last month reported that its third quarter revenues jumped 164 percent year over year and 23 percent sequentially.

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.